Acta clinica Croatica, Vol. 64. No. 4, 2025.
Izvorni znanstveni članak
https://doi.org/10.20471/acc.2025.64.04.16
Real-World Clinical Outcomes of Advanced Non-Small Cell Lung Cancer Patients with High PD-L1 Expression (≥ 50%) Treated with Pembrolizumab Monotherapy: Evidence from a Single University Hospital in Central Europe
Jasmina Marić Brozić
; Department of Oncology and Nuclear Medicine, Sestre milosrdnice University Hospital Center, Zagreb, Croatia; School of Medicine, University of Zagreb, Zagreb, Croatia
Hrvoje Brčić
orcid.org/0009-0000-7530-8921
; Department of Oncology and Nuclear Medicine, Sestre milosrdnice University Hospital Center, Zagreb, Croatia
*
Klara Brčić
; Department of Hematology, Clinic for Internal Medicine, Sestre milosrdnice University Hospital Center, Zagreb, Croatia
Kristina Urch
; Department of Oncology and Nuclear Medicine, Sestre milosrdnice University Hospital Center, Zagreb, Croatia
Neva Purgar Levarda
; Department of Oncology and Nuclear Medicine, Sestre milosrdnice University Hospital Center, Zagreb, Croatia
Jasna Radić
; Department of Oncology and Nuclear Medicine, Sestre milosrdnice University Hospital Center, Zagreb, Croatia; School of Medicine, University of Zagreb, Zagreb, Croatia
Ana Fröbe
; Department of Oncology and Nuclear Medicine, Sestre milosrdnice University Hospital Center, Zagreb, Croatia; School of Dental Medicine, University of Zagreb, Zagreb, Croatia
* Dopisni autor.
Sažetak
Pembrolizumab, a programmed death-1 (PD-1) immune checkpoint inhibitor, has
demonstrated significant survival benefits as monotherapy in clinical trials for advanced non-small cell
lung cancer (NSCLC) with high programmed death ligand-1 (PD-L1) expression (PD-L1 ≥ 50%).
Real-world data on this topic is growing every day.
We conducted a single-center, retrospective observational study at Sestre milosrdnice University
Hospital Center in Zagreb, Croatia, analyzing the outcomes of patients with advanced NSCLC (stage
IIIB–IV) and high PD-L1 expression treated with pembrolizumab as first-line monotherapy between
March 2018 and March 2023. Demographic and clinical data including treatment response, adverse
events, progression-free survival (PFS) and overall survival (OS) were analyzed using descriptive statistics
and the Kaplan-Meier survival analysis, with multivariate Cox regression for covariate assessment.
Seventy-two patients met the inclusion criteria. Median follow-up was 49 months. Median PFS
and OS were 13 months (95% CI: 5–20 months) and 24 months (95% CI: 14–46 months), respectively.
One-year OS rate was 66.67%. Pembrolizumab demonstrated a favorable safety profile, with adverse
events consistent with those reported in clinical trials.
This study highlights the real-world effectiveness and safety of pembrolizumab monotherapy for
advanced NSCLC with high PD-L1 expression in a single-center cohort. Survival outcomes were consistent
with clinical trial data.
Ključne riječi
Pembrolizumab; NSCLC; PD-1; PD-L1; Immunotherapy
Hrčak ID:
344730
URI
Datum izdavanja:
31.12.2025.
Posjeta: 490 *